A groundbreaking study emerging from the Garvan Institute of Medical Research has illuminated a covert biological mechanism that elucidates why estrogen receptor-positive (ER+) breast cancer has a propensity to relapse long after initial treatment success. Published in the prestigious journal Nature Communications, this research reveals the presence of rogue cancer cells that adopt a unique slow-cycling state, enabling them to persist in a quiescent yet active phase. These diminutive cell populations form microscopic tumors or micrometastases that evade conventional detection, silently advancing in distant organs over the course of years or even decades.
While advancements in primary breast cancer treatment have achieved remarkable efficacy, one of the paramount challenges remains the mitigation of late relapse. Adjuvant hormone therapies, administered for extended durations spanning five to ten years, serve to suppress tumor regrowth effectively. Nevertheless, up to 30% of ER+ breast cancer patients encounter incurable metastatic recurrence during or after this period, a major contributor to breast cancer mortality in Australia and worldwide. The persistence of malignant cells despite aggressive systemic therapy has perplexed oncologists and researchers, driving the pursuit of novel insights into metastatic dormancy and escape.
Historically, the phenomenon of cancer relapse has been attributed primarily to dormant tumor cells in niches such as bone marrow or other organs, which enter a complete standstill or hibernation state before reawakening. Contrasting this long-standing model, the new findings articulate an alternative yet complementary pathway wherein a subpopulation of breast cancer cells never fully arrests their cell cycle. Instead, they continue to divide at an exceedingly slow pace, maintaining minimal but persistent growth. This mechanism allows micrometastases to gradually develop beneath the radar of standard imaging technologies and biochemical markers.
Associate Professor Liz Caldon, lead investigator and head of the research team at Garvan, elucidates, “While dormant cells represent one form of therapeutic evasion, our work uncovers a covert population of cells that remain metabolically and reproductively active, albeit at a significantly reduced rate. These slow-cycling cells resist hormone therapy not by halting division but by strategically slowing their proliferation to survive and eventually seed metastatic disease.” This paradigm shift in understanding challenges the classical dichotomy of active versus dormant cancer cells and opens new frontiers for therapeutic intervention.
The study meticulously characterized these slow-dividing cells by isolating them over several years using sophisticated cell sorting and growth assays. Contrary to prevailing assumptions linking metastatic potential with rapid proliferation, experimental models demonstrated that slow-cycling cells possess formidable migratory and invasive capabilities. When introduced into animal models, these cells homed efficiently to organs such as bone and lung, establishing micrometastatic colonies. This phenomenon underscores that cellular velocity is not a prerequisite for metastatic competence and reframes the narrative around tumor aggressiveness.
At the molecular level, the team discovered that the Rac1 signaling pathway is instrumental in orchestrating the survival and motility of these slow-growing cells. Rac1, a small GTPase known for its role in cytoskeletal reorganization and cell migration, was found to be upregulated, facilitating the covert expansion and dissemination of micrometastases. Advanced biosensor imaging techniques enabled real-time visualization of Rac1 activation within live cancer cells, providing compelling evidence of its functional relevance in this slow-cycling population.
Crucially, pharmacological inhibition of Rac1 yielded promising therapeutic outcomes. Experimental Rac1 inhibitors effectively curtailed tumor growth and lowered metastatic burden in patient-derived xenograft models, highlighting this pathway as a viable target for future drug development. By interfering with the cellular machinery that sustains slow proliferation and survival, such strategies may thwart metastatic relapse, transforming the clinical landscape for ER+ breast cancer patients.
The implications of these findings ripple profoundly through the realms of oncology and personalized medicine. Current clinical practice relies heavily on standardized hormone therapy regimens, often applied uniformly across patient populations without nuanced molecular stratification. Understanding the biology underpinning slow-cycling cancer cells paves the way for precision approaches that monitor and target these elusive populations. It suggests the potential utility of biomarkers for slow-cycling cells to predict therapeutic resistance and inform treatment duration more accurately.
Associate Professor Caldon emphasizes the translational potential: “Identifying and targeting slow-growing cancer cells provides a new therapeutic lever to prevent metastatic escape. By refining our grasp of their biology, we hope to not only improve surveillance strategies during and post-hormone therapy but also develop adjunct treatments capable of eradicating these hidden reservoirs before they culminate in fatal relapse.”
The quest continues with ongoing investigations spearheaded by the Caldon Lab, which aims to validate Rac1 inhibitors in preclinical and clinical contexts. Evaluating whether these agents can be safely integrated into standard care as prophylactic measures against recurrence constitutes a key priority. Such therapeutic innovation represents a paradigm shift, moving beyond the conventional focus on rapidly dividing tumor cells toward a more comprehensive assault on cancer’s adaptive survival tactics.
Furthermore, the discovery deepens our understanding of tumor heterogeneity—a hallmark of cancer complexity. Tumors comprise diverse cellular subpopulations, each equipped with distinct survival mechanisms. The coexistence of highly proliferative and slow-cycling cells confers adaptability, ensuring tumor persistence under selective pressure from systemic therapies. Targeting these varied subpopulations holistically is essential for durable remission.
This pioneering study underscores the dynamic interplay between cancer cell biology, therapeutic resistance, and clinical outcomes in breast cancer. It encapsulates a leap forward in unravelling the intricate mechanisms governing metastatic dormancy and escape. As the field embraces this nuanced perspective, the prospect of improving patient prognosis through innovative, targeted interventions grows brighter.
In sum, the Garvan team’s revelations cast light on a cryptic facet of cancer biology that has eluded detection for decades. By spotlighting slow-cycling ER+ breast cancer cells as crucial drivers of late relapse, they offer a poignant reminder that cancer’s endurance hinges not only on rapid proliferation but also on strategic stealth. This insight fuels hope for novel therapies that can dismantle the cancer’s silent march and change the trajectory of metastatic breast cancer forever.
Subject of Research: Animals
Article Title: Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling
News Publication Date: 11-May-2026
Web References: 10.1038/s41467-026-70683-x
Image Credits: Garvan Institute
Keywords: Breast cancer, Cancer cells, Metastasis, Cancer treatments, Combination therapies, Hormone therapy, Cancer medication, Chemotherapy
Tags: adjuvant hormone therapy limitationsbreast cancer late relapse mechanismsbreast cancer micrometastasis detection challengesbreast cancer mortality and late relapsecancer cell quiescence and metastasisestrogen receptor-positive breast cancer dormancyGarvan Institute breast cancer researchhormone therapy resistance in breast cancermetastatic dormancy in cancer cellsmetastatic recurrence in ER+ breast cancermicrometastases in breast cancerslow-cycling cancer cells in breast tumors
